ClinicalTrials.gg
CompletedNCT00972374Updated Apr 24, 2013Results posted

Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function

A Phase 2 interventional study of 400 ug Brimonidine Implant and 200 ug Brimonidine Implant in Rhegmatogenous Macula-off Retinal Detachment, sponsored by Allergan. Completed at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-24.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Retinal Detachment with a site in United States — 3 open to participants now, 3 under way, 1 of them phase 3. Retinal Detachment · United States.

Enrollment
12th of 27
44 · median 40
Started
2009
with 2 others
Phase 2
5 of 32
none open now
Registered
5th of 32
by date
Lead sponsor
1 of 32
Allergan

Among the 32 studies in Retinal Detachment with a site in United States, this one is the 12th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2009, is one of 5 in phase 2, and was the 5th registered.

Retinal Detachment

199 studies on the registry are indexed under Retinal Detachment; 29 are open to participants now.

Browse Retinal Detachment studies →

Open to participants now

3 of the 32 studies in Retinal Detachment with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Retinal Detachment studies recruiting now, 15 (71%) set no upper age limit and 4 (19%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Retinal Detachment with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.

03

Conditions studied

  • Rhegmatogenous Macula-off Retinal Detachment

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The macula-off retinal detachment must have been caused by a rupture (rhegmatogenous in etiology)
  • The repair of the macula-off retinal detachment must have occurred at least 6 months before the Day 1 visit in the study eye
  • The repair must have been deemed an anatomic success and required no more than one macular re-attachment procedure
  • The visual acuity score must be between 20/50 and 20/320 in the study eye

Exclusion criteria

Exclusion Criteria:

  • Any sight-threatening ocular condition in the study eye other than the ruptured retinal detachment
  • Anticipated need for ocular surgery during the 12-month study period
  • Any injectable, periocular, or intravitreal treatment to study eye within 6 months prior to screening (eg, triamcinolone acetonide)
  • Any injectable, periocular, or intravitreal anti-VEGF treatment to the study eye within 3 months prior to screening (eg, Avastin or Lucentis)
  • Any infectious condition in the study eye
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    400 ug Brimonidine Implant

    400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.

    Drug: 400 ug Brimonidine Implant

  • Experimental
    200 ug Brimonidine Implant

    200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.

    Drug: 200 ug Brimonidine Implant

  • Sham comparator
    Sham (no implant)

    Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.

    Other: Sham (no implant)

Interventions

  • 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.

    Also known as: Brimonidine Tartrate PS DDS®

  • 200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.

    Also known as: Brimonidine Tartrate PS DDS®

  • OtherSham (no implant)

    Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. The percentage of patients with at least a 15-letter increase in BCVA in the study eye is reported.

    Time frame: Month 3

Secondary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

    Time frame: Baseline, Month 3

Other outcomes

  1. Percentage of Patients With Intraocular Pressure (IOP) < 10 mmHg in the Study Eye at Any Follow up Visit

    IOP is the fluid pressure inside the eye. The percentage of patients with IOP \< 10 millimeters of mercury (mmHg) in the study eye at any follow up visit is presented.

    Time frame: 12 Months

07

Results

Posted Apr 24, 2013

Participant flow

Participant flow — Overall Study
Milestone400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Started151514
Completed131513
Not completed201

Outcome measures

PrimaryPercentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. The percentage of patients with at least a 15-letter increase in BCVA in the study eye is reported.

Time frame:
Month 3
Reported as:
Number · Percentage of Patients
Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
Percentage of Patients400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye6.76.70
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

Time frame:
Baseline, Month 3
Reported as:
Mean · Number of Letters Read Correctly
Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
Number of Letters Read Correctly400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Baseline46.6 ± 13.6953.3 ± 8.4650.3 ± 10.92
Change from Baseline at Month 36.0 ± 6.233.1 ± 6.784.8 ± 4.64
Other pre-specifiedPercentage of Patients With Intraocular Pressure (IOP) < 10 mmHg in the Study Eye at Any Follow up Visit

IOP is the fluid pressure inside the eye. The percentage of patients with IOP \< 10 millimeters of mercury (mmHg) in the study eye at any follow up visit is presented.

Time frame:
12 Months
Reported as:
Number · Percentage of Patients
Percentage of Patients With Intraocular Pressure (IOP) < 10 mmHg in the Study Eye at Any Follow up Visit
Percentage of Patients400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Percentage of Patients With Intraocular Pressure (IOP) < 10 mmHg in the Study Eye at Any Follow up Visit20.026.728.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
400 ug Brimonidine Implant—0/15 (0%)7/15 (46.7%)
200 ug Brimonidine Implant—2/15 (13.3%)12/15 (80%)
Sham (no Implant)—2/14 (14.3%)9/14 (64.3%)
Most frequent serious events
Most frequent serious events
Event400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Prostate Cancer [y]Neoplasms benign, malignant and unspecified (incl cysts and polyps)0/91/100/9
Myocardial InfarctionCardiac disorders0/150/151/14
Strabismus CorrectionSurgical and medical procedures0/150/151/14
HaemorrhoidsGastrointestinal disorders0/151/150/14
Most frequent other events
Showing 10 of 62
Most frequent other events
Event400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)
Conjunctival HaemorrhageEye disorders3/151/152/14
Eye PainEye disorders1/153/151/14
Conjunctival HyperaemiaEye disorders2/151/151/14
Eye PruritusEye disorders2/150/150/14
Hypotony of EyeEye disorders1/152/150/14
Intraocular Pressure DecreasedInvestigations1/152/150/14
DepressionPsychiatric disorders0/152/150/14
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/91/100/9
Conjunctival OedemaEye disorders1/151/151/14
Retinal HaemorrhageEye disorders1/150/151/14

Baseline characteristics

Age Continuous
Age Continuous(Years)400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)Total
Mean54.2 ± 17.1254.3 ± 20.3656.1 ± 15.1954.9 ± 17.35
Sex: Female, Male
Sex: Female, Male(Participants)400 ug Brimonidine Implant200 ug Brimonidine ImplantSham (no Implant)Total
Female65516
Male910928
08

Study locations

6 sites
  • Abilene, Texas, United States
  • New Delhi, India
  • Tel Aviv, Israel
  • Seoul, Korea, Republic of
  • Makati, Philippines
  • London, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Oct 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 2 years 6 months after primary completion. A results delay was requested in Oct 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2009
First posted
Sep 4, 2009
Start
Nov 2009
Primary completionActual
Oct 2010
CompletionActual
Jul 2011
Results delay requested
Oct 20, 2011
Results first posted
Apr 24, 2013
Last update
Apr 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00972374
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Sep 4, 2009
Start date
Nov 2009
Primary completion
Oct 2010
Completion
Jul 2011
Results posted
Apr 24, 2013
Last update
Apr 24, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion